This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 11 of 12 for:    ONC201

Expanded Access Program for ONC201 to Treat Recurrent Histone H3 Mutant Glioma

Expanded access is currently available for this treatment.
Verified July 2017 by Oncoceutics, Inc.
Information provided by (Responsible Party):
Oncoceutics, Inc. Identifier:
First received: April 20, 2017
Last updated: July 14, 2017
Last verified: July 2017
The objective of this expanded access program is to provide ONC201 on a single patient compassionate use basis to eligible adult subjects with recurrent glioma that exhibits a missense histone H3 mutation .

Condition Intervention
Glioma Drug: ONC201

Study Type: Expanded Access     What is Expanded Access?
Available for Individual Patients

Resource links provided by NLM:

Further study details as provided by Oncoceutics, Inc.:


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  1. Confirmed evidence of glioma with disease progression from immediately prior therapy or refractory to the immediately prior treatment.
  2. Evidence of missense histone H3 tumor mutation detected by a CLIA assay, either by IHC or DNA sequencing, that includes but is not restricted to K27M, G34R, and G34V in H3.3.
  3. Male or Female age ≥18 years.
  4. Karnofsky Performance Status (KPS) ≥ 50%
  5. ECOG performance status ≤ 2.
  6. Adequate organ and marrow function as defined below:

    1. Absolute neutrophil count ≥1,000/mm3 without growth factor use ≤ 7 days prior to treatment.
    2. Hemoglobin >8.0 mg/dL without red blood cell transfusion ≤ 3 days prior to treatment.
    3. Total serum bilirubin <1.5 X upper limit of normal (ULN)
    4. AST (SGOT)/ALT (SGPT) ≤2 X ULN; ≤ 5 X ULN if there is liver involvement secondary to tumor.
    5. Serum creatinine ≤ 1.5 X ULN (OR creatinine clearance ≥ 60 mL/min/1.73 m2)
  7. Ability to understand and the willingness to sign a written informed consent document.
  8. Ability to swallow capsules
  9. Female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. Male patients must be surgically sterile or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. The decision of effective contraception will be based on the judgment of the principal investigator or a designated associate.

Exclusion Criteria:

  1. Known active bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV).
  2. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
  3. Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism.
  4. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, or in the judgment of the investigator would make the patient inappropriate for entry into the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT03134131

Contact: Clinical Operations Oncoceutics 1-888-ONCORXS ext 1

United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Oncoceutics, Inc.
  More Information

Responsible Party: Oncoceutics, Inc. Identifier: NCT03134131     History of Changes
Other Study ID Numbers: ONC011
Study First Received: April 20, 2017
Last Updated: July 14, 2017

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue processed this record on August 18, 2017